$ATNF
180 Life Sciences Corp.

2024 Q4 Form 10-Q Financial Statement

#000121390024098508 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $576.4K $2.430M
YoY Change -76.28% -28.92%
% of Gross Profit
Research & Development $251.6K $972.1K
YoY Change -74.12% 66.69%
% of Gross Profit
Depreciation & Amortization $13.85K $30.00K
YoY Change -53.83% 275.94%
% of Gross Profit
Operating Expenses $979.1K $3.538M
YoY Change -72.33% -12.75%
Operating Profit -$979.1K -$3.538M
YoY Change -72.33% -12.75%
Interest Expense $23.65K $11.63K
YoY Change 103.28% 58.33%
% of Operating Profit
Other Income/Expense, Net $142.4K -$9.073M
YoY Change -101.57% -47.95%
Pretax Income -$836.7K -$12.61M
YoY Change -93.37% -41.31%
Income Tax -$2.345M
% Of Pretax Income
Net Earnings -$836.7K -$10.27M
YoY Change -91.85% -52.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.85 -$1.29
Diluted Earnings Per Share -$0.85 -$1.29
COMMON SHARES
Basic Shares Outstanding 1.977M shares 969.6K shares 5.318M shares
Diluted Shares Outstanding 980.6K shares 7.952M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $194.9K $2.700M
YoY Change -92.78% -24.76%
Cash & Equivalents $194.9K $2.663M
Short-Term Investments
Other Short-Term Assets $986.1K $600.0K
YoY Change 64.35% -98.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.225M $3.371M
YoY Change -63.65% -48.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $9.244M $1.587M
YoY Change 482.44% 1.43%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.244M $1.587M
YoY Change 482.44% -94.3%
TOTAL ASSETS
Total Short-Term Assets $1.225M $3.371M
Total Long-Term Assets $9.244M $1.587M
Total Assets $10.47M $4.958M
YoY Change 111.17% -85.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.091M $1.713M
YoY Change 22.04% 68.74%
Accrued Expenses $466.3K $2.376M
YoY Change -80.37% 13.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $473.1K $300.0K
YoY Change 57.71% -6.74%
Total Short-Term Liabilities $6.384M $4.807M
YoY Change 32.81% 1.73%
LONG-TERM LIABILITIES
Long-Term Debt $10.57K $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.57K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.384M $4.807M
Total Long-Term Liabilities $10.57K $0.00
Total Liabilities $6.736M $5.107M
YoY Change 31.89% -38.17%
SHAREHOLDERS EQUITY
Retained Earnings -$129.2M -$126.1M
YoY Change 2.48% 47.22%
Common Stock $103.00 $674.00
YoY Change -84.72% -82.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.734M -$149.3K
YoY Change
Total Liabilities & Shareholders Equity $10.47M $4.958M
YoY Change 111.17% -85.56%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$836.7K -$10.27M
YoY Change -91.85% -52.22%
Depreciation, Depletion And Amortization $13.85K $30.00K
YoY Change -53.83% 275.94%
Cash From Operating Activities -$223.7K -$1.770M
YoY Change -87.36% -50.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -476.1K 2.450M
YoY Change -119.43% -55.35%
NET CHANGE
Cash From Operating Activities -223.7K -1.770M
Cash From Investing Activities
Cash From Financing Activities -476.1K 2.450M
Net Change In Cash -699.7K 680.0K
YoY Change -202.9% -64.05%
FREE CASH FLOW
Cash From Operating Activities -$223.7K -$1.770M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38105
dei Entity Registrant Name
EntityRegistrantName
180 LIFE SCIENCES CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1890354
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 El Camino Real Bldg. 4
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
507-0669
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1976999 shares
CY2024Q3 us-gaap Cash
Cash
194920 usd
CY2023Q4 us-gaap Cash
Cash
1975799 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030461 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1664107 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1225381 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3639906 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9244475 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1619570 usd
CY2024Q3 us-gaap Assets
Assets
10469856 usd
CY2023Q4 us-gaap Assets
Assets
5259476 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2090827 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1892611 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
466335 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1869814 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
473143 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1034124 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
58 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6383830 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5062616 usd
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
10574 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19936 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
341678 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
304657 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6736082 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5387209 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1026930 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1026930 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
534719 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
534719 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
103 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
54 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135955083 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
130117209 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2983072 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2901339 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129238340 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127343657 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3733774 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-127733 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10469856 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5259476 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
251577 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
972113 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1105086 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2339863 usd
CY2024Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
151138 usd
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
132880 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
455345 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
481027 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
576378 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2433194 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3357868 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9204122 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
979093 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3538187 usd
us-gaap Operating Expenses
OperatingExpenses
4918299 usd
us-gaap Operating Expenses
OperatingExpenses
12025012 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-979093 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3538187 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4918299 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12025012 usd
CY2024Q3 us-gaap Other Income
OtherIncome
118723 usd
us-gaap Other Income
OtherIncome
2870789 usd
CY2024Q3 us-gaap Interest Expense Other
InterestExpenseOther
13633 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
11634 usd
us-gaap Interest Expense Other
InterestExpenseOther
41442 usd
us-gaap Interest Expense Other
InterestExpenseOther
34796 usd
CY2023Q3 atnf Loss On In Process Research Development Asset Impairment
LossOnInProcessResearchDevelopmentAssetImpairment
9063000 usd
atnf Loss On In Process Research Development Asset Impairment
LossOnInProcessResearchDevelopmentAssetImpairment
9063000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2036 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-58 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-69776 usd
CY2024Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
37283 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
194211 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
142373 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9072598 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3023616 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9028020 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-836720 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12610785 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1894683 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21053032 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2345025 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2345025 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-836720 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
us-gaap Net Income Loss
NetIncomeLoss
-1894683 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67332 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51316 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-81733 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36712 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-904052 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10214444 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1976416 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18671295 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-62.81
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-62.81
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
980641 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
418524 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
846529 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
297834 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
980641 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
418524 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
846529 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
297834 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-127733 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
489 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
236062 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1069744 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6460 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-954466 usd
CY2024Q2 atnf Stock Issued During Period Value Issued For Settlement Of Liabilities
StockIssuedDuringPeriodValueIssuedForSettlementOfLiabilities
523251 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22308 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
11781 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20861 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-417987 usd
CY2024Q3 atnf Stock Issued During Period Value Issued For Settlement Of Liabilities
StockIssuedDuringPeriodValueIssuedForSettlementOfLiabilities
190011 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16456 usd
CY2024Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4849346 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-836720 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67332 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3733774 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11343918 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
557421 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4762078 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
663 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7139924 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2337706 usd
CY2023Q2 atnf Adjustments To Additional Paid In Capital Warrant Issued1
AdjustmentsToAdditionalPaidInCapitalWarrantIssued1
117 usd
CY2023Q2 atnf Shares Issued In Value Connection Offering
SharesIssuedInValueConnectionOffering
382182 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
551310 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3680169 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15267 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6715803 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60624 usd
CY2023Q3 atnf Stock Issued During Period Value Issuance Of August2023 Prefunded Warrants And Common Warrants Net
StockIssuedDuringPeriodValueIssuanceOfAugust2023PrefundedWarrantsAndCommonWarrantsNet
2459282 usd
CY2023Q3 atnf Stock Issued During Period Value Issued From Exercise Of August2023 Prefunded Warrants
StockIssuedDuringPeriodValueIssuedFromExerciseOfAugust2023PrefundedWarrants
66 usd
CY2023Q3 atnf Stock Issued During Period Value Issued In Connection With August2023 Offering
StockIssuedDuringPeriodValueIssuedInConnectionWithAugust2023Offering
245348 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
583994 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51316 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-149327 usd
us-gaap Net Income Loss
NetIncomeLoss
-1894683 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
60624 usd
atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
274826 usd
atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
1692725 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-9063000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
61408 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
83015 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-58 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-69776 usd
atnf Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
194211 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2345025 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1443471 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1273033 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
4060 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-99169 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
317541 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
51227 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-542260 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
94778 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
141366 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1364777 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
9945798 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-529906 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8762209 usd
atnf Proceeds From Exercise Of Prefunded Warrants From The Amendment To August2023 Offering
ProceedsFromExerciseOfPrefundedWarrantsFromTheAmendmentToAugust2023Offering
489 usd
atnf Proceeds From Sale Of April2023 Offering Stock And Warrants
ProceedsFromSaleOfApril2023OfferingStockAndWarrants
2999882 usd
atnf Proceeds From Sale Of August2023 Offering Stock And Warrants
ProceedsFromSaleOfAugust2023OfferingStockAndWarrants
2999606 usd
atnf Proceeds From Exercise Of April2023 Offering Prefunded Warrants
ProceedsFromExerciseOfApril2023OfferingPrefundedWarrants
117 usd
atnf Proceeds From Exercise Of August2023 Offering Prefunded Warrants
ProceedsFromExerciseOfAugust2023OfferingPrefundedWarrants
66 usd
atnf Payment Of Offering Costs In Connection With April2023 Offering Stock And Warrants
PaymentOfOfferingCostsInConnectionWithApril2023OfferingStockAndWarrants
-279994 usd
atnf Payment Of Offering Costs In Connection With August2023 Offering Stock And Warrants
PaymentOfOfferingCostsInConnectionWithAugust2023OfferingStockAndWarrants
-294976 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1005856 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
985175 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1005367 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4439526 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-245606 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15093 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1780879 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4307590 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1975799 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6970110 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194920 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2662520 usd
us-gaap Interest Paid Net
InterestPaidNet
12078 usd
us-gaap Interest Paid Net
InterestPaidNet
21722 usd
atnf Common Stock Issued For Settlement Of Liabilities
CommonStockIssuedForSettlementOfLiabilities
523251 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
7622041 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp., formerly known as KBL Merger Corp. IV (“<span style="text-decoration:underline">180LS</span>”, or together with its subsidiaries, the “<span style="text-decoration:underline">Company</span>”), was a blank check company organized under the laws of the State of Delaware on September 7, 2016. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Corp. (“<span style="text-decoration:underline">180</span>”, f/k/a 180 Life Sciences Corp. and CannBioRx Life Sciences Corp.) is a wholly-owned subsidiary of the Company and was incorporated in the State of Delaware on January 28, 2019. The Company is located in the United States (“<span style="text-decoration:underline">U.S.</span>”) and is a medical pharmaceutical company focused upon unmet medical needs in the areas of inflammatory diseases, fibrosis, and chronic pain by employing innovative research and, where appropriate, combination therapies, through 180’s three wholly-owned subsidiaries, 180 Therapeutics L.P. (“<span style="text-decoration:underline">180 LP</span>”), CannBioRex Pharmaceuticals Corp. (“<span style="text-decoration:underline">CBR Pharma</span>”), and Katexco Pharmaceuticals Corp. (“<span style="text-decoration:underline">Katexco</span>”). 180 LP, CBR Pharma and Katexco are together, the “<span style="text-decoration:underline">180 Subsidiaries.</span>” Katexco was incorporated on March 7, 2018 and CBR Pharma was incorporated on March 8, 2018, under the provisions of the British Corporation Act of British Columbia. 180 LP was formed as a limited partnership on September 6, 2013, in Delaware. Additionally, 180’s wholly-owned subsidiaries Katexco Callco, ULC, Katexco Purchaseco, ULC, CannBioRex Callco, ULC, and CannBioRex Purchaseco, ULC were formed in the Canadian Province of British Columbia on May 31, 2019 to facilitate the acquisition of Katexco, CBR Pharma and 180 LP. On July 1, 2021, the assets and liabilities of the Canadian companies (Katexco and CBR Pharma) were transferred to their respective subsidiaries, which are Katexco Pharmaceuticals Corp. (“<span style="text-decoration:underline">Katexco U.S.</span>”) and CannBioRex Pharma Limited (“<span style="text-decoration:underline">CBR Pharma U.K.</span>”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. We have three product development platforms:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">fibrosis and anti-tumor necrosis factor (“<span style="text-decoration:underline">TNF</span>”);</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">drugs which are derivatives of cannabidiol (“<span style="text-decoration:underline">CBD</span>”) or cannabigerol (“<span style="text-decoration:underline">CBG</span>”) analogues (“<span style="text-decoration:underline">SCAs</span>”); and</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">alpha 7 nicotinic acetylcholine receptor (“<span style="text-decoration:underline">α7nAChR</span>”).</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to restrictions in the Company’s resources, the Company has slowed down research and development activities significantly in the SCA platform and the anti-TNF platform. The Company has not made progress on the α7nAChR platform and has suspended further research and development activity in this program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is currently evaluating all options to monetize its existing assets, in addition to exploring other strategic alternatives to maximize value for its stockholders. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2024, the Company entered into an Asset Purchase Agreement (the “<span style="text-decoration:underline">Purchase Agreement</span>”) with Elray Resources, Inc. (“<span style="text-decoration:underline">Elray</span>”). Pursuant to the Purchase Agreement, Elray agreed to sell us certain source code and intellectual property relating to a “back-end technology platform” which is a key component of creating an online blockchain casino (the “<span style="text-decoration:underline">Purchased Assets</span>”) Elray agreed to provide support and assistance to the Company in connection with the building and launching of a fully operational casino operation utilizing the Purchased Assets.</p>
atnf Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1 pure
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129238340 usd
CY2024Q3 atnf Working Capital Deficit
WorkingCapitalDeficit
5158449 usd
us-gaap Net Income Loss
NetIncomeLoss
-1894683 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-529906 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the fair value of financial instruments, warrants, options, derivative liabilities and research and development (R&amp;D) tax credits and accruals. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and may cause actual results to differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p>
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67332 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51316 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-81733 usd
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
1467 usd
CY2024Q3 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
350 usd
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
2952 usd
CY2023Q3 us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
1485 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1462084 usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
9063000 usd
CY2022Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
0 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1880000 usd
CY2022Q4 us-gaap Amount Of Impairment To Carrying Amount Of Regulatory Assets
AmountOfImpairmentToCarryingAmountOfRegulatoryAssets
3342084 usd
CY2022 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
0 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
9063000 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
9063000 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
9063000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
571898 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
934990 usd
CY2023Q4 atnf Research And Development Expense Tax Credit Receivable Current
ResearchAndDevelopmentExpenseTaxCreditReceivableCurrent
440161 usd
CY2024Q3 atnf Professional Fees Current
ProfessionalFeesCurrent
414217 usd
CY2023Q4 atnf Professional Fees Current
ProfessionalFeesCurrent
279039 usd
CY2024Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
44346 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
9917 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030461 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1664107 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.68
atnf Capitalized Intangible Cost
CapitalizedIntangibleCost
7622041 usd
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9866140000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2162430000000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
621665000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
542860000000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9244475000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1619570000000 usd
CY2024Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
13851 usd
CY2023Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
32693 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
61408 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
83015 usd
CY2023Q4 atnf Accrued Consulting Fees
AccruedConsultingFees
645081 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184846 usd
CY2023Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
49999 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87875 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
530383 usd
CY2024Q3 atnf Research And Development Fees
ResearchAndDevelopmentFees
311588 usd
CY2023Q4 atnf Research And Development Fees
ResearchAndDevelopmentFees
378683 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
56363 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
70923 usd
CY2024Q3 atnf Other Accrued Liabilities
OtherAccruedLiabilities
10509 usd
CY2023Q4 atnf Other Accrued Liabilities
OtherAccruedLiabilities
9899 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
466335 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1869814 usd
us-gaap Noninterest Income Other
NoninterestIncomeOther
1039364 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
58 usd
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
191 usd
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
249 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-249 usd
CY2023Q4 us-gaap Loans Payable
LoansPayable
1054060 usd
CY2024Q3 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
777702 usd
us-gaap Debt Instrument Repaid Principal
DebtInstrumentRepaidPrincipal
1005856 usd
atnf Debt Cancellation
DebtCancellation
343436 usd
atnf Effect Of Foreign Exchange Rates
EffectOfForeignExchangeRates
1247 usd
CY2024Q3 us-gaap Loans Payable
LoansPayable
483717 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1034124 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
473143 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19936 usd
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
10574 usd
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
13633 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
11633 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
41442 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
34796 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2024Q3 atnf Accrued Interest Current
AccruedInterestCurrent
56363 usd
CY2023Q4 atnf Accrued Interest Current
AccruedInterestCurrent
70923 usd
CY2024Q4 us-gaap Premiums Receivable Proceeds From Sale Of Receivables
PremiumsReceivableProceedsFromSaleOfReceivables
178514 usd
CY2024Q3 atnf Financing Agreement
FinancingAgreement
777702 usd
CY2024Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
17300000 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
685000 shares
atnf Percenatge Of Outstanding Shares
PercenatgeOfOutstandingShares
0.60 pure
CY2024Q3 atnf Divided Shares
DividedShares
1000000 shares
us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.40 pure
CY2024Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.318
CY2024Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
1318000 shares
CY2021Q3 us-gaap Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate
ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate
11286570 usd
CY2023Q2 atnf Payments Of Full Amount Of Fees Total
PaymentsOfFullAmountOfFeesTotal
714557 usd
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
6776686 usd
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
50000 usd
CY2024Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
25171 usd
us-gaap Repayments Of First Mortgage Bond
RepaymentsOfFirstMortgageBond
50000 usd
CY2022Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
2000000 usd
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
125000 usd
us-gaap Legal Fees
LegalFees
83333 usd
CY2024Q3 atnf Advance Payment Of Reimbursement Fee
AdvancePaymentOfReimbursementFee
125000 usd
CY2024Q3 atnf Received Amount
ReceivedAmount
76639 usd
CY2024Q1 atnf Funding Subsequents
FundingSubsequents
5000000 usd
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
18750 usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
25000 shares
us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
5000000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57328 shares
CY2024Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
20000 shares
CY2024Q3 atnf Common Stock Term1
CommonStockTerm1
P2Y
CY2024Q3 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1.95
CY2024Q3 atnf Change In Relative Fair Value
ChangeInRelativeFairValue
101471 usd
CY2024Q3 atnf Fair Value Of Issuance Of Option
FairValueOfIssuanceOfOption
28591 usd
CY2024Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.95
CY2024Q2 atnf General Consulting Services
GeneralConsultingServices
150 usd
CY2024Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
0 usd
CY2024Q2 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
175313 usd
CY2024Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
175313 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
216000 usd
CY2024Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
250000 usd
CY2024Q3 us-gaap Termination Loans
TerminationLoans
75000 usd
CY2024Q2 us-gaap Payments For Fees
PaymentsForFees
15000 usd
CY2024Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
28012 shares
CY2024Q3 us-gaap Business Combination Consideration Transferred Other1
BusinessCombinationConsiderationTransferredOther1
96000 usd
CY2024Q3 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
36682 usd
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1
CY2023Q4 atnf Percentage Of Shares Outstanding
PercentageOfSharesOutstanding
0.20 pure
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-149327 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
35102 shares
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.35
CY2023Q3 atnf Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
2700000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000 usd
CY2023Q4 atnf Purchaser Agreed To Pay
PurchaserAgreedToPay
830769 usd
CY2023Q4 atnf Unexercised Pre Funded Warrant
UnexercisedPreFundedWarrant
257205 shares
CY2023Q4 atnf Common Stock Warrants To Purchase
CommonStockWarrantsToPurchase
477058 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.23
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2029-02-16
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17788 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
633.95
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.95
atnf Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Termin Years Granted
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingTerminYearsGranted
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14897 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22891 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y8M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
22354 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
49.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y7M6D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16456 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
274826 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
644618 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1753349 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60624 usd
CY2023Q3 atnf Amortization Of Stock Options
AmortizationOfStockOptions
583994 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60624 usd
atnf Amortization Of Stock Options
AmortizationOfStockOptions
1692725 usd
CY2024Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
563361 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1504768 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
216284 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
atnf Warrants Excercisable Term
WarrantsExcercisableTerm
P5Y
us-gaap Fee Income
FeeIncome
50000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
15000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2023Q3 us-gaap Other Income
OtherIncome
usd
us-gaap Other Income
OtherIncome
usd
CY2024Q3 atnf Loss On In Process Research Development Asset Impairment
LossOnInProcessResearchDevelopmentAssetImpairment
usd
atnf Loss On In Process Research Development Asset Impairment
LossOnInProcessResearchDevelopmentAssetImpairment
usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
atnf Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
usd
atnf Proceeds From Exercise Of Prefunded Warrants From The Amendment To August2023 Offering
ProceedsFromExerciseOfPrefundedWarrantsFromTheAmendmentToAugust2023Offering
usd
atnf Proceeds From Sale Of April2023 Offering Stock And Warrants
ProceedsFromSaleOfApril2023OfferingStockAndWarrants
usd
atnf Proceeds From Sale Of August2023 Offering Stock And Warrants
ProceedsFromSaleOfAugust2023OfferingStockAndWarrants
usd
atnf Proceeds From Exercise Of April2023 Offering Prefunded Warrants
ProceedsFromExerciseOfApril2023OfferingPrefundedWarrants
usd
atnf Proceeds From Exercise Of August2023 Offering Prefunded Warrants
ProceedsFromExerciseOfAugust2023OfferingPrefundedWarrants
usd
atnf Payment Of Offering Costs In Connection With April2023 Offering Stock And Warrants
PaymentOfOfferingCostsInConnectionWithApril2023OfferingStockAndWarrants
usd
atnf Payment Of Offering Costs In Connection With August2023 Offering Stock And Warrants
PaymentOfOfferingCostsInConnectionWithAugust2023OfferingStockAndWarrants
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
atnf Common Stock Issued For Settlement Of Liabilities
CommonStockIssuedForSettlementOfLiabilities
usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
usd
CY2024Q3 atnf Research And Development Expense Tax Credit Receivable Current
ResearchAndDevelopmentExpenseTaxCreditReceivableCurrent
usd
CY2024Q3 atnf Accrued Consulting Fees
AccruedConsultingFees
usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
CY2024Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
atnf Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Intrinsic Value Granted Total
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueIntrinsicValueGrantedTotal
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
atnf Share Based Compensation Arrangement By Share Based Payment Award Options Forfeiture In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodTotalIntrinsicValue
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q3 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
5950 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001690080

Files In Submission

Name View Source Status
0001213900-24-098508-index-headers.html Edgar Link pending
0001213900-24-098508-index.html Edgar Link pending
0001213900-24-098508.txt Edgar Link pending
0001213900-24-098508-xbrl.zip Edgar Link pending
atnf-20240930.xsd Edgar Link pending
ea0220680-10q_180life.htm Edgar Link pending
ea022068001ex31-1_180life.htm Edgar Link pending
ea022068001ex31-2_180life.htm Edgar Link pending
ea022068001ex32-1_180life.htm Edgar Link pending
ea022068001ex32-2_180life.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
atnf-20240930_def.xml Edgar Link unprocessable
atnf-20240930_lab.xml Edgar Link unprocessable
atnf-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0220680-10q_180life_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atnf-20240930_cal.xml Edgar Link unprocessable